NASDAQ, TASE: MZOR

May, 2018

1
FORWARD LOOKING STATEMENT

This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation
Reform Act of 1995 and other securities laws. Forward-looking statements are not historical facts, and are based
upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently
uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no
assurance that management’s expectations, beliefs and projections will be achieved and actual results may differ
materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are
subject to risks and uncertainties that could cause actual performance or results to differ materially from those
expressed in the forward-looking statements, including risks detailed in Mazor Robotics Ltd.’s (“Mazor Robotics” or
the “Company”) annual reports on Form 20-F filed with the U.S. Securities and Exchange Commission. The following
solutions are not yet cleared for use: Navigation, Guidewireless

Forward-looking statements speak only as of the date the statements are made. The Company assumes no
obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances,
changes in assumptions or changes in other factors affecting forward-looking information except to the extent
required by applicable securities laws. If the Company does update one or more forward-looking statements, no
inference should be drawn that the Company will make additional updates with respect thereto or with respect to
other forward-looking statements.

mazorrobotics.com 2
Healing through Innovation
Strategic Vision

Mazor as a growing patient-focused, global innovative leader,

delivering advanced image based robotic guidance products in and out of spine.

• Growth through continued market leadership and focus on partnership with Medtronic

• Evidence Based Medicine with predictability and efficiency for the healthcare community

• Strategic and Economic Value through innovative products and procedural solutions for our
partners

• Innovation for safer and predictable surgery with clinically-evidenced outcomes for patients

mazorrobotics.com 3
Current Snapshot
From Vision to Experienced Market Leader

Strategic partnership Mazor Core ™ technology with

with Medtronic three generations of commercial
(Mazor X in spine) products

60+ peer-reviewed articles and

strong evidence of improved
patient outcomes

33,000+ Patients , 100s

Surgical technique used for
of surgeons, wide
precise placement of 230,000 +
spectrum of procedures
implants

mazorrobotics.com 4
Mazor Robotic Guidance Systems
Predictability, Precision and Efficiency through Innovation

1. Planning 2. Guided Execution 3. Intra Op Verification

mazorrobotics.com 5
 Mazor Core
Surgical Planning Suite
• 3D analytics and virtual tools
developed to determine procedure
goals and surgical plan. The suite of
tools allow creation of a “surgical
blueprint” that separates the
surgeon’s analytical planning
process from the actual surgery.
• During surgery, the surgeon
executes the plan as an efficient and
predictable procedure with no
anatomical surprises. Implants are
pre-selected and prepped, the team
knows what to expect.
Anatomy Recognition Engine
• The advanced anatomy recognition
engine reads images and recognizes
anatomical features based on advanced
and proprietry algorithms.
• The engine is fundamental for planning
and serves as the underlying technology
for features such as vertebral
segmentation, image registration and
alignment calculations.
Patient Connection Platform
• Set of biocompatible devices that rigidly
affix the robotic system/arm to the
patient’s skeletal anatomy during surgery,
ensuring precision through a stable, solid
connection.
• This unique feature maintains patient-
machine unity during the operation and
is a major contributor to accuracy.
Cross-modality image registration
• Sophisticated registration tool with the
ability to analyze and match images from
different modalities and body positions,
e.g. pre-op CT with intra-op fluoroscopy.
• Each vertebra is registered independently
of the others and irrespective of
modality, date of the image, or patient
position.
mazorrobotics.com 6
Commercial Success
Launch and Adoption of Mazor X

2017 Execution (0-50 Systems) Worldwide Installed Base

* Renaissance MazorX

150 6 72

100

143
50 108 116
83
63
27 41
0 18

• Intuitive Surgical – Launch 1999 – Data estimated based on published data

• Renaissance launch 2011, Mazor X Launch 2016 mazorrobotics.com 7
Medtronic and Mazor
Activity Spectrum – Mazor X Global Commercial Partner*
Commercial Activity
100’s strong Medtronic sales
team driving:
• Growing Mazor X Installed
Base
• Supporting Procedure
Volume
* For Spinal procedures only
Market Development Joint Development
Mazor X & Mazor X w/Nav Mazor X Platform w/Nav
Medtronic
Investment in:
• Market Development
• Medical Education
• Bioskill Labs
• Society Meetings
• Promotion
• Public Relations
• Sales Training
• Launch Plan
mazorrobotics.com 8
Evidence-based Medicine
From Accuracy to Outcomes

Consistent Accuracy with Improved Outcomes Proven Reduction in Complications and Revisions (1)
18.1%

5.2% 5.8%
0.9%

1 2

Dr. Thomas Sweeney,, Orthopaedic Surgeon, FL Proven Reduction in Exposure to Radiation (2)

I have been doing minimally-invasive surgery since

1999. Mazor Robotics Renaissance®'s revolutionary
approach to spinal surgery has transformed my
practice so I no longer need to do any open thoracic
and lumbar surgery..
___________________________
1. Based on published data: Cannestra, e-poster NASS 2014; Kantelhardt, ESJ 2011; Ringel, ESJ 2012, Roser, 2013.
2. Freehand represents the average fluoro radiation exposure during a freehand operation as a baseline for comparison to Renaissance only.
mazorrobotics.com 9
Evidence-Based Medicine
MIS-ReFRESH Prospective Study
(Presented at NASS 2017 – Emerging Technologies)

Significantly fewer complications in robotic arm

• Compared to fluoro-guided, robotic-guided surgeries were at
5.3 times LOWER risk for a complication

Significantly fewer revisions in robotic arm

• Compared to fluoro-guided, robotic-guided surgeries were at
7.1 times LOWER risk for a revision

78% less fluoro time/screw in robotic arm

Caveats:
• Interim report – only 92 control patients
• Only 2 surgeons in control arm
• 6-month average follow-up
• High event rate in fluoro-guided arm

mazorrobotics.com 10
How could Mazor Core impact health economics?

• If a surgeon changes 100 Fluoro-guided MIS cases to Mazor Core MIS per year:
Event
Eventtype
type Baseline
Baseline number of
number Relative
Relative Risk* Anticipated
Anticipated number of Reduction
Reduction in number
in Cost
Costofofevent** Reduced
Reduced costs
costs
events* events* of events*
of events* Risk* number of number of event**
events* events*

Complications
Complications 27
27 5.3
5.3 55 22
22 $9K
$9K $200K
$198K

Revisions
Revisions 44 7.1
7.1 11 33 $28K
$28K $84K
$84K

Total speculated savings /100 surgeries/year $282K

* Projected based on MIS ReFRESH data

**Based on Medicare costs (From Culler 2013 & Adogwa 2016)

mazorrobotics.com 11
Updated Business Model
Three Sources

Capital Sales Per Case Revenue Per System Revenue

Mazor X Distributor Sales Disposable Kits Annual Service revenues

Renaissance: Direct Sales Synergy fee revenue:*

(*) under certain conditions

mazorrobotics.com 12
Renaissance
New Business Model

• Technology
• Mazor Core + Brain
• 10% of accounts include Renaissance Brain

• Business Model:
• Geographic areas where Mazor X regulatory clearance is not imminent
• Target Market: Medicare accredited ASCs in the United States

• International
• Global Sales Organization
• Active distributors in China, Taiwan, Australia, Thailand, Vietnam, Germany

• Pipeline
• Simplified workflow to fit single level procedure

mazorrobotics.com 13
Revenue Breakdown
Year Ended December, 2017

$70,000
$64,947
Disposables, Service and Others
$60,000
Systems

$50,000 43%

$40,000
$36,379

$30,000
$26,096 46%
$19,983 $21,208
$20,000 49% 57%
$12,175 32% 43%
$10,000 $5,904 29% 54%
$3,973 68% 57% 51%
26% 30%
70% 71%
$0 74%

Gross margin 76% 68% 76% 79% 79% 78% 72% 64%

mazorrobotics.com 14
Income Statement

Income Statement

Year Ended December 31, 3 Months Ended March 31,

($ in thousands) 2017 2016 2018 2017
Revenue $64,947 $36,379 $15,507 $11,719
Cost of sales $23,684 $10,330 $6,465 $4,149
Gross Profit $41,263 $26,049 $9,042 $7,570
% margin 64% 72% 58% 65%

Operating Expenses
Research and development, net $8,192 $5,736 $2,387 $1,792
Selling and marketing, net $39,499 $33,637 $6,081 $9,893
General and administrative $7,375 $5,697 $2,022 $1,571
Total operating expenses $55,066 $45,070 $10,490 $13,256
% of revenue 85% 124% 68% 113%

Loss from operations ($13,803) ($19,021) ($1,448) ($5,686)

Net loss ($12,419) ($18,668) ($1,277) ($5,232)

mazorrobotics.com 15
Balance Sheet

Consolidated Statements of Financial Position

As of March 31, As of December 31,

($ in thousands) 2018 2017
Assets
Cash and Cash equivalent $47,003 $46,376
Short-term investments $62,484 $56,708
Trade receivables $1,608 $5,460
Other accounts receivable $2,445 $2,054
Inventory $7,954 $7,864
Total current assets $121,494 $118,462

Total non-current assets $12,399 $12,534

Total Assets $133,893 $130,996

Current liabilities $15,277 $16,819

Total non-current liabilities $472 $414

Equity $118,144 $113,763

Total liabilities and Equity $133,893 $130,996

mazorrobotics.com 16
Mazor Robotics
2018

Strategic Partnership New Market Leverage Robotics

with Medtronic for Mazor X Strategy for the Renaissance Spine and Out-of-Spine
mazorrobotics.com 17